EU unprepared for no-deal Brexit, health experts warn

pharmafile | August 12, 2019 | News story | Sales and Marketing EU, Euroepan Union, UK, brexit, pharma 

European health experts have warned that a no-deal Brexit could worsen medicines shortages in the European Union.

Speaking to Reuters, Andy Powrie-Smith, an official at the European Federation of Pharmaceutical Industries and Associations, said: “Despite intensive preparation by industry for every scenario, a no-deal Brexit risks disruption to the supply of medicines” throughout the EU.

The comments come as Prime Minister Boris Johnson doubled down on the deadline of 31 October, as he suggested that Britain would leave whether it was with a deal or not.

However health experts have warned that some drugs may not have the required regulatory approval to allow them to be brought in from Britain by the deadline on 31 October.

Equally, more thorough customs controls could disrupt supplies of drugs and active pharmaceutical ingredients coming from Britain to the EU.

Eric Van Neuten, the chief executive officer of Febelco, Belguim’s largest medicines wholesaler, said: “there will be some problems and delays in the supply chain due to border protocols, but I think we will be able to manage.”

Meanwhile the EMA said they are now well prepared for Britain’s departure from the EU as it suggested it had finalised authorisations for nearly all of the 400 drugs under its watch.

Currently, around 45 million packs of medicines are shipped from Britain to the rest of the EU each month, while 37 million packs of medicine come the other way.

Louis Goss

Related Content

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …


Novartis acquires Chinook Therapeutics for $3.5bn

Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …

Latest content